10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

CDKN2D Antibody (monoclonal) (M08)

Mouse monoclonal antibody raised against a full-length recombinant CDKN2D.
Catalog # AT1483a

Product Information

Application	WB, IP, E
Primary Accession	P55273
Other Accession	BC001822
Reactivity	Human
Host	mouse
Clonality	monoclonal
Isotype	IgG2b Kappa
Clone Names	2E11
Calculated MW	17700

Additional Information

Gene ID	1032
Other Names	Cyclin-dependent kinase 4 inhibitor D, p19-INK4d, CDKN2D
Target/Specificity	CDKN2D (AAH01822, 1 a.a. ~ 166 a.a) full-length recombinant protein with GST tag. MW of the GST tag alone is 26 KDa.
Dilution	WB~~1:500~1000 IP~~N/A E~~N/A
Format	Clear, colorless solution in phosphate buffered saline, pH 7.2 .
Storage	Store at -20°C or lower. Aliquot to avoid repeated freezing and thawing.
Precautions	CDKN2D Antibody (monoclonal) (M08) is for research use only and not for use in diagnostic or therapeutic procedures.


Background

The protein encoded by this gene is a member of the INK4 family of cyclin-dependent kinase inhibitors. This protein has been shown to form a stable complex with CDK4 or CDK6, and prevent the activation of the CDK kinases, thus function as a cell growth regulator that controls cell cycle G1 progression. The abundance of the transcript of this gene was found to oscillate in a cell-cycle dependent manner with the lowest expression at mid G1 and a maximal expression during S phase. The negative regulation of the cell cycle involved in this protein was shown to participate in repressing neuronal proliferation, as well as spermatogenesis. Two alternatively spliced variants of this gene, which encode an identical protein, have been reported.


References

Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. Cunningham JM, et al. Br J Cancer, 2009 Oct 20. PMID 19738611.Identification of aberrant cell cycle regulation in Epstein-Barr virus-associated nasopharyngeal carcinoma by cDNA microarray and gene set enrichment analysis. Zhang W, et al. Acta Biochim Biophys Sin (Shanghai), 2009 May. PMID 19430707.Candidate gene analysis using imputed genotypes: cell cycle single-nucleotide polymorphisms and ovarian cancer risk. Goode EL, et al. Cancer Epidemiol Biomarkers Prev, 2009 Mar. PMID 19258477.Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. Agarwal SK, et al. J Clin Endocrinol Metab, 2009 May. PMID 19141585.Common genetic variation in candidate genes and susceptibility to subtypes of breast cancer. Mavaddat N, et al. Cancer Epidemiol Biomarkers Prev, 2009 Jan. PMID 19124506.

Images




Antibody Reactive Against Recombinant Protein.Western Blot detection against Immunogen (44 KDa) .




Western Blot analysis of CDKN2D expression in transfected 293T cell line by CDKN2D monoclonal antibody (M08), clone 2E10.

Lane 1: CDKN2D transfected lysate(17.7 KDa).
Lane 2: Non-transfected lysate.



Immunoprecipitation of CDKN2D transfected lysate using anti-CDKN2D monoclonal antibody and Protein A Magnetic Bead (U0007), and immunoblotted with CDKN2D MaxPab rabbit polyclonal antibody.



Detection limit for recombinant GST tagged CDKN2D is 0.1 ng/ml as a capture antibody.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.